AVEO Pharmaceuticals Completes Enrollment In Phase 2 Clinical Trial Of AV-951 In Patients With Metastatic Renal Cell Carcinoma AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that they have completed enrollment in their 200-patient Phase 2 clinical trial of AV-951 in patients with metastatic renal cell carcinoma (mRCC).
Source: www.medicalnewstoday.comSpelling Difficulties And Handedness Explored Children who can read and have good phonetic skills - the ability to recognize the individual sounds within words - may still be poor spellers. In a paper published in the May 2008 issue of Cortex, Elizabeth Eglinton and Marian Annett, at the School of Psychology of Leicester, UK, show that this subgroup of poor spellers is more likely to be right-handed than other poor spellers.
Source: www.medicalnewstoday.comMajor Independent Trial Demonstrates Significant Anticancer Benefit Of Zometa(R) In Premenopausal Women With Early-Stage Breast Cancer New data presented today showed that Zometa(R) (zoledronicacid) offered a significant anticancer benefit for premenopausal women withhormone-sensitive, early-stage breast cancer. The study found that Zometawhen added to hormone therapy, following surgery, significantly reduced therisk of cancer returning or death by 36% beyond clinical benefits achievedwith hormone therapy alone.
Source: www.medicalnewstoday.comCatumaxomab, Representing A New Generation Of Antibodies, Proved Efficient And Safe In Malignant Ascites Treatment with the trifunctional antibody catumaxomabsignificantly prolongs puncture-free survival in patients with malignantascites, according to the results from a Phase II/III trial presented at the44th American Society of Clinical Oncology (ASCO) congress.
Source: www.medicalnewstoday.comECRI Institute And Phoenix Data Systems To Offer CMMS Integration Package New service helps hospitals with capital equipment inventory and patient safety alerts and recalls PLYMOUTH MEETING, PA - ECRI Institute, an independent nonprofit that researches the best approaches to improving patient care, and Phoenix Data Systems, Inc.
Source: www.medicalnewstoday.comPotential Impact Of Limiting Erythropoiesis-Stimulating Agent Availability On Frequency Of Blood Transfusions Data from three observational studies reported at the American Society of Clinical Oncology (ASCO) Annual Meeting evaluated transfusion-related outcomes in cancer chemotherapy patients with various hemoglobin (Hb) levels prior to or during administration of erythropoiesis-stimulating agents (ESAs).
Source: www.medicalnewstoday.comTarceva(R) Delivers Benefits Across Broad Range Of Non-Small Cell Lung Cancer Patients - Confirmed By New Data New data presented at ASCO 2008 from TRUST1, the largest non-small cell lung cancer (NSCLC) Phase IV trial ever conducted, show that a broad range of NSCLC patients treated with Tarceva (erlotinib) experience clinical benefits including longer survival, better quality of life, control of disease symptoms and control of cancer progression.
Source: www.medicalnewstoday.comI Do Not See It, But My Brain Knows What It Means Patients suffering from "hemineglect" cannot attend to, and hence cannot see, things presented to their left side. However, sometimes these ignored stimuli may be processed without awareness.
Source: www.medicalnewstoday.comHSE Safety Alert To The Printing Industry: Fatalities On Hand-Fed Platen Machines, UK The
Health and Safety Executive (HSE) has issued a safety alert aimed at employers in the printing industry who use hand-fed platen machines. This follows two fatal incidents in the last 13 months where machine operators have been crushed between the platens. In both cases the machines were being operated in 'dwell' mode at the time of the intervention.
Source: www.medicalnewstoday.comJournal Of Pharmaceutical Innovation Publishes Ground-breaking Scientific Papers On Reshaping Pharmaceutical Quality The June 2008 issue of the Journal of Pharmaceutical Innovation (JPI) is publishing the first scientific papers outlining the progress made on ISPE's Product Quality Lifecycle Implementation (PQLI) initiative.
Source: www.medicalnewstoday.comLabels: No Prescription, Online Pharmacy
# posted by Network @ 4:00 AM
